Gaidano G, Contarini M, Pastore C, Saglio G, Matera L
Department of Biomedical Sciences and Human Oncology, University of Turin, Ospedale San Luigi, Italy.
Proc Soc Exp Biol Med. 1996 Nov;213(2):196-205. doi: 10.3181/00379727-213-44051.
The development of non-Hodgkin's lymphomas (NHL) is one of the major complications of AIDS. Although several biologic aspects of AIDS-related NHL have been clarified, their sensitivity to immune system cytotoxic effectors has not been tested. In this study, we have investigated the susceptibility of one major AIDS-related NHL type, Burkitt's-type lymphoma (BL), to the cytotoxic activity of lymphokine-activated killers (LAK) and prolactin-activated killers (PAK), which were generated from peripheral blood mononuclear cells upon stimulation with interleukin-2 (in the case of LAK cells) and prolactin (in the case of PAK cells). The sensitivity of AIDS-related BL to in vitro raised cytotoxic effectors was compared with that of BL variants of the general population, including sporadic BL and endemic BL. The data show that AIDS-related BL is susceptible to cytolysis by LAK cells, whereas both LAK and PAK cells can efficiently kill endemic BL. In contrast, sporadic BL showed resistance to all cytotoxic effectors tested. Intriguingly, in the case of AIDS-related and endemic BL suboptimal doses of interleukin-2 in combination with prolactin displayed a cytotoxic effect similar to that of LAK cells, suggesting a synergistic activity of the two agents. Overall, these data corroborate the notion that the distinct BL variants differ in their biologic features despite their morphologic and genetic similarity.
非霍奇金淋巴瘤（NHL）的发生是艾滋病的主要并发症之一。尽管艾滋病相关NHL的一些生物学方面已得到阐明，但其对免疫系统细胞毒性效应物的敏感性尚未得到检测。在本研究中，我们调查了一种主要的艾滋病相关NHL类型，即伯基特型淋巴瘤（BL），对淋巴因子激活的杀伤细胞（LAK）和催乳素激活的杀伤细胞（PAK）细胞毒性活性的敏感性，这些细胞是由外周血单个核细胞在白细胞介素-2（对于LAK细胞）和催乳素（对于PAK细胞）刺激下产生的。将艾滋病相关BL对体外培养的细胞毒性效应物的敏感性与普通人群的BL变体（包括散发性BL和地方性BL）进行了比较。数据显示，艾滋病相关BL对LAK细胞的细胞溶解敏感，而LAK和PAK细胞都能有效杀伤地方性BL。相比之下，散发性BL对所有测试的细胞毒性效应物均表现出抗性。有趣的是，对于艾滋病相关和地方性BL，次优剂量的白细胞介素-2与催乳素联合使用显示出与LAK细胞相似的细胞毒性作用，表明这两种药物具有协同活性。总体而言，这些数据证实了这样一种观点，即尽管不同的BL变体在形态和遗传上相似，但其生物学特征存在差异。
